双时间点[18F]FLT-PET鉴别增殖性与非增殖性组织
该研究纳入85例未经治疗的初诊单灶乳腺癌女性,在注射[18F]FLT后三个时间点(PET30、PET60、PET80)行PET采集,分析肿瘤、肝脏、骨髓、主动脉、肌肉及对侧正常乳腺的SUVmax变化。结果显示仅增殖组织(乳腺病灶和骨髓)SUVmax随时间显著升高,而肝脏、肌肉、主动脉显著下降,对侧乳腺无显著变化。提示双时间点[18F]FLT-PET可能有助于鉴别残留肿瘤与瘢痕组织。
要点
- 乳腺病灶SUVmax在30至80分钟显著升高(p<0.0001)。
- 骨髓(T4和肱骨头)SUVmax随时间显著升高(p<0.0001)。
- 肝脏、肌肉、主动脉SUVmax随时间显著下降,对侧乳腺无显著变化。
核心结论
- [18F]FLT-SUVmax在30至80分钟仅于增殖组织升高,可能有助于鉴别残留肿瘤与瘢痕组织。
研究设计与样本
- 前瞻性研究纳入85例未经治疗的初诊单灶乳腺癌女性,注射[18F]FLT后于33.94±8.01分钟(PET30)、61.45±8.30分钟(PET60)、81.06±12.12分钟(PET80)行三次PET采集。
- 对肿瘤、肝脏、骨髓(第4胸椎T4和肱骨头)、降主动脉、肌肉(三角肌)及对侧正常乳腺进行SUV半定量分析,采用重复测量方差分析和Tukey事后检验比较各部位三个时间点的SUVmax。
主要发现
- 乳腺病灶SUVmax在PET30、PET60、PET80分别为5.58±3.80、5.97±4.56、6.19±4.42,随时间显著升高(p<0.0001)。
- 骨髓T4的SUVmax分别为8.21±3.17、9.64±3.66、10.85±3.63,肱骨头分别为3.36±1.79、3.87±1.89、4.39±2.00,均随时间显著升高(p<0.0001)。
- 肝脏SUVmax分别为6.79±2.03、6.24±1.99、5.57±1.74,肌肉分别为0.95±0.28、0.93±0.29、0.86±0.20,主动脉分别为1.18±0.34、1.01±0.32、0.97±0.30,均随时间显著下降(p值分别为<0.0001、0.027、<0.0001)。
- 对侧乳腺SUVmax分别为0.8364±0.40、0.78±0.38、0.80±0.35,无显著差异。
关键数值与推荐
- 乳腺病灶SUVmax在30至80分钟升高,骨髓(T4和肱骨头)SUVmax亦升高(p<0.0001)。
- 肝脏、肌肉、主动脉SUVmax随时间下降(p<0.0001、p=0.027、p<0.0001)。
- 对侧正常乳腺SUVmax无显著变化。
临床怎么用
- 双时间点[18F]FLT-PET可观察增殖组织SUVmax随时间升高,或有助于鉴别残留肿瘤与瘢痕组织。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For differentiating tumor from inflammation and normal tissues, fluorodeoxyglucose ([18F]FDG) dual time point PET could be helpful. Albeit [18F]FLT is more specific for tumors than [18F]FDG; we explored the role of dual time point [18F]FLT-PET for discriminating benign from malignant tissues. METHODS: Before any treatment, 85 womens with de novo unifocal breast cancer underwent three PET acquisitions at 33.94 ± 8.01 min (PET30), 61.45 ± 8.30 min (PET60), and 81.06 ± 12.12 min (PET80) after [18F]FLT injection. Semiquantitative analyses of [18F]FLT uptake (SUV) were carried out on tumors, liver, bone marrow (4th thoracic vertebra (T4) and humeral head), descending thoracic aorta, muscle (deltoid), and contralateral normal breast. Repeated measures ANOVA tests and Tukey's posttests were used to compare SUVmax of each site at the three time points. RESULTS: There was a significant increase in SUVmax over time for breast lesions (5.58 ± 3.80; 5.97 ± 4.56; 6.19 ± 4.42; p < 0.0001) (m ± SD for PET30, PET60, and PET80, respectively), and bone marrow (for T4, 8.21 ± 3.17, 9.64 ± 3.66, 10.85 ± 3.63, p < 0.0001; for humeral head, 3.36 ± 1.79, 3.87 ± 1.89, 4.39 ± 2.00, p < 0.0001). A significant decrease in SUVmax over time was observed for liver (6.79 ± 2.03; 6.24 ± 1.99; 5.57 ± 1.74; p < 0.0001), muscle (0.95 ± 0.28; 0.93 ± 0.29; 0.86 ± 0.20; p < 0.027), and aorta (1.18 ± 0.34; 1.01 ± 0.32; 0.97 ± 0.30; p < 0.0001). No significant difference was observed for SUVmax in contralateral breast (0.8364 ± 0.40; 0.78 ± 0.38; 0.80 ± 0.35). CONCLUSION: [18F]FLT-SUVmax increased between 30 and 80 min only in proliferating tissues. This could be helpful for discriminating between residual tumor and scar tissue.
引用
- Lovinfosse P, Rousseau C, Pierga JY, et al. Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues. EJNMMI Res. 2019. PMID: 31832803. doi:10.1186/s13550-019-0579-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。